IlluminOss Medical announced that the first patient has been enrolled in its EU Light Fix trial for the treatment of humerus fractures due to metastatic carcinoma.
The trial will be led by orthopedic oncologist Reinhard Windhager, MD, of the University Clinic of Vienna.
The trial will enroll up to 45 patients at approximately 10 centers in Austria, Germany and the Netherlands. It aims to assess the safety and efficacy of the IlluminOss System, a minimally invasive system that allows for fracture fixation through patient-specific intramedullary implants.
"The IlluminOss System will potentially allow orthopedic surgeons to approach impending and actual fractures resulting from metastatic malignancy in a groundbreaking way that will benefit both the surgeon and the patient," said Prof. Windhager. "I am pleased to lead the first Light Fix trial in the EU and hope our efforts will help validate an approach to orthopedic surgery that can provide treatment options for patients that previously had little or no recourse and also potentially lessen complications and improve outcomes."
More articles on devices:
NuVasive, Medtronic patent saga continues — 5 key updates
InVivo goes from illiquid to a top-traded stock: 5 key notes
6 key notes on Mazor Robotics' short interest decline